Jason Mast , 2025-05-08 19:40:00
Insitro, the closely watched AI biotech from the Stanford professor and entrepreneur Daphne Koller, said Thursday it was laying off 22% of its staff, or around 60 people.
It’s part of a series of cuts that have hit well-backed startups over the last couple years, amid a prolonged downturn in biotech fundraising. A few startups have shut down altogether. Others have slashed early stage research to conserve resources for their first clinical trials.
“This proactive action streamlines our operations, sharpens our focus on key priorities, and extends our runway into 2027,” an Insitro spokesperson said in a statement.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
